QT Vascular wins patent infringement case
Medical supplies group QT Vascular and its chief executive officer, Eitan Konstantino, have successfully defended themselves against a patent infringement lawsuit filed by another medical company AngioScore, the company said in a Singapore Exchange filing on Wednesday.
This means that QT Vascular can continue to sell its "Chocolate PTA" balloon catheter without impediment, the Catalist-listed group said in its statement.
It said that after a seven-day trial in California, the jury decided that QT Vascular's Chocolate PTA does not infringe the patent in question.
AngioScore, a specialty balloon angioplasty firm that was co-founded by Dr Konstantino, had claimed that Chocolate PTA infringed the '119 Patent - a patent that claims a very specific design for an angioplasty balloon catheter and a non-deployable stent.
However, QT Vascular said on Wednesday that the jury's unanimous verdict "confirms that Chocolate is substantially different from the design disclosed in the '119 patent".
Based on the verdict, the group does not expect to incur any liability on the patent claim, it said.
BT is now on Telegram!
For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes
Companies & Markets
US: Nasdaq, S&P tumble as Netflix, chip stocks drag
Europe: L’Oreal gains cap third week of declines
Telegram messaging service to allow Tether stablecoin payments
Hong Kong regulator to probe PwC auditing role over Evergrande
US: S&P, Dow open flat as Middle East jitters ease, Netflix weighs on Nasdaq
DBS puts 46 retail units, HDB shops on market for S$210 million